medigraphic.com

2002, Número 1-2

<< Anterior Siguiente >>

Rev Hosp M Gea Glz 2002; 5 (1-2)


Tratamiento farmacológico para la diabetes mellitus

Mateos SCN, Zacarías CR

Idioma: Español
Referencias bibliográficas: 50
Paginas: 33-41
Archivo PDF: 106.32 Kb.


RESUMEN

El tratamiento de la diabetes mellitus está dirigido a aliviar los síntomas, mejorar la calidad de vida y la prevención de complicaciones agudas y crónicas. Las estrategias de tratamiento se dividen en no farmacológicas como la dieta y el ejercicio y las farmacológicas que se dividen en medicamentos orales e insulina. Los principales grupos de fármacos orales los constituyen las sulfonilureas, las biguanidas, los inhibidores de glucosidasas intestinales, las tiazolidinedionas y las meglitinidas. Cada grupo de fármacos orales tiene características propias por mecanismo de acción, indicaciones y contraindicaciones específicas así como efectos adversos, por lo que su conocimiento es indispensable para su adecuado uso. La terapia con insulina tradicionalmente utilizada en la diabetes tipo 1 ha ampliado su uso recientemente con la indicación en la diabetes tipo 2 que puede utilizarse sola o combinada con medicamentos orales, con lo que pueden lograrse mejores metas de control y conseguir los objetivos deseados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2001;24(S1), S4-S19.

  2. BaeKKeskov S, Neilsen JH, Marner B, Bilde T, Ludwisson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children with immunoprecipitate human pancreatic islet cell proteins. Nature 298;1982:167-69.

  3. Lu J, Li Q, Xieh, Chen Z, Borovitskaya AE, Maclaren NK et al. Identification of second transmembrana proteintyrosine phosphatasa, IA-2B, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-Kdaryptic fragment. Proc Nat Acad Sci USA 1996;93: 2307-2311.

  4. Reaven GM, Bernstein R, Davis D, Olefsky JM. Nonketotic diabetes mellitus: insulin deficiency of insulin resistance? AM J. Med 1976;60:80-88.

  5. Bogardus C, Lillioja S, Mott DM, Hollen-Beck, Reavrn G. Relationship between degree of obesity and in vivo insulin action in man. Am J Phishyol 1985;248:E286-E291.

  6. Reaven GM. Role insulin resistance in human disease. Diabetes 1988; 37: 1595-607.

  7. Feinglos MN, Bethels A. Oral agent therapy in the treatment of diabetes. Diabetes Care 2001;22(S1):S44-S47.

  8. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 2001;24(S1):S44-S47.

  9. American Diabetes Association: Diabetes mellitus and exercise. Diabetes Care 2001;24(S1):S51-S54.

  10. American Diabetes Association: standards of medical care for patients with diabetes mellitus. Diabetes Care 20001;24(S1):S33-S43.

  11. Palumbo PJ. Glycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clinic Proceedings 2001;76(6):609-618.

  12. Leif C, Groop MD. Sulfonylureas in NIDDM. Diabetes Care 1992;15(6):737-753.

  13. Endocrinology and metabolism. Clinic of North Am 1997;26:511-522.

  14. DeFronzo, Ralph. MD. Pharmacologic Therapy for Type 2 diabetes mellitus. Ann Intern Med 1999;131(4):281-303.

  15. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS et al. Thiazolidinedione produce a conformational change in peroxisome proliferator-actived receptor-gamma; binding and activation correlate with antidiabetic actions in db/db mice. Endocrinol 1996;137:4189-4195.

  16. Dwans T, Dand, Stephen D. Ismall Iramoctal: increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000;23(4):518-523.

  17. American Diabetes Association: Screenny her diabetes. Diabetes Care 2001:24 S.

  18. Riddle Matheww. Combining sulfonylureas and other oral agents. The American Journal of Medicine 2000;108:155-225.

  19. Dornhorst A. Insulinotropic meglitinides analogues. Lancet 2001;358:1709-16.

  20. Landggraff R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drug and Aging 2000;17(5):411-425.

  21. Halas Cynthia J. Nateglinide. American Journal of Health-System Pharmacy 2001;58(13):1200-1205.

  22. Gegick CG, Alltheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001;7(3):169-9.

  23. Golddstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes Technology and Therapeutics 1999;1(3):267-75.

  24. Sood V, Colleran K, Burge MR. Diabetes Technology and Therapeutics 2000;2(3):429-40.

  25. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endoc and Metab 2001;86(7):3452-6.

  26. Schoojans K, Auwerx J. Thiazolidinediones: ann update. Lancet 2000;355(9208):1008-10.

  27. Luna B, Feinglos MN. Oral agents in the management of type diabetes mellitus. American Family Physician 2001;63(9):1747-56.

  28. Iwata M, Haruta T, Usui I, Takata Y, Takano A et al. Pioglitazone ameliorates tumor necrosis factor-alpha- induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes 2001;50(5): 1083-92.

  29. Peters AL. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. Am J Managed Care 2001;7(3 S):s87-95.

  30. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Progress in Horm, one Research. 2001;56: 265-94.

  31. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annual Review of Medicine 2001;53:239-57.

  32. Valsamakis G, Kumar S. Insulin action enhancers for the management of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2000;1(7):1413-21.

  33. Rett K. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obesity and Metabolism 1999;1(S1):S8-16.

  34. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obesity and Metabolism 1999 1999;1(3):165-72.

  35. Matthaei S, Stumvoll M, Kellerer M. Haring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocrine Reviews 2000;2(6):585-618.

  36. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs and Aging 2000;17(5):411-25.

  37. Rendell MS, Kirchain WR. Pharmacotherapy of type 2 diabetes mellitus. Annals of Pharmacotherapy 2000;34(7-8):878-95.

  38. Fuchtenbush M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes. Exp Clin Endoc Diab , 2000;108(3):108(3):151-63.

  39. Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sciences 2000;67(20): 2405-16.

  40. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108(S6a):15S-22S.

  41. Mayer B, Davidson MD. Duarte, California, Anne L. Peters, MD. An overview of Metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102:99-110.

  42. Clinical Diabetes. Endocrinology and Metabolis of Clinical North Americ 1997.

  43. Buse JB. Overview of current therapeutic options in type 2 diabetes. Diabetes Care 1999;21(S3):c65-C70.

  44. DeFronzo R, Goodman MA et al. Efficacy of Metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;31:541-549.

  45. Stumvoll, Nurjahan, Perrielo G et al. Metabolic effects of Metformin in non-insulin-dependent diabetes mellitus. New Engl J Med 1995;31:550-554.

  46. Croofford BO. Metformin. New Engl J Med 1995;333(9):588-89.

  47. Hanele YRI-Jarvinen, MD. Combination therapies with insulin in type 2 diabetes.

  48. Berger M, Jorges V, Muhlhauser I. Rationals for use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 22(S3):C71-75.

  49. Langraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drug and Aging 2000;17(5):411-25.

  50. Zinman B. Insulin regimens and strategies for IDDM. Diabetes Care 1993;16:24-28.




2020     |     www.medigraphic.com